Related Experiment Video
Updated: Apr 10, 2026

05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
1.1K
Flexible Multimodal Neuroimaging Fusion for Alzheimer's Disease Progression Prediction
Benjamin Burns1, Yuan Xue1,2, Douglas W Scharre3
1Department of Computer Science and Engineering, The Ohio State University, Columbus, USA.
Summary
PerM-MoE improves Alzheimer's disease progression prediction using multiple neuroimaging types, even when data is missing. This novel method enhances accuracy compared to existing models for forecasting cognitive decline.
Area of Science:
- Neuroscience
- Medical Imaging
- Artificial Intelligence
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by variable rates of cognitive decline.
- Accurate prediction of AD progression is crucial for patient care and clinical trial design.
- Multimodal neuroimaging data integration offers potential for improved prediction, but existing models struggle with missing data during inference.
Purpose of the Study:
- To develop a flexible multimodal model for Alzheimer's disease progression prediction that performs well even with significant missing neuroimaging data.
- To introduce PerM-MoE, a novel sparse mixture-of-experts approach with independent modality routers.
- To compare the performance of PerM-MoE against state-of-the-art models and unimodal approaches in predicting cognitive decline.
Main Methods:
- Utilized T1-weighted MRI, FLAIR, amyloid beta PET, and tau PET data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort.
- Developed PerM-MoE, a sparse mixture-of-experts model featuring independent routers for each neuroimaging modality.
- Evaluated model performance in predicting two-year changes in Clinical Dementia Rating-Sum of Boxes (CDR-SB) scores under various missing data scenarios, comparing against Flex-MoE and unimodal models.
Main Results:
- PerM-MoE demonstrated superior performance in predicting Alzheimer's disease progression (CDR-SB change) across most tested levels of missing neuroimaging data.
- The proposed PerM-MoE model showed more effective utilization of available experts compared to the state-of-the-art Flex-MoE.
- The independent router mechanism in PerM-MoE enhances flexibility and predictive power in data-scarce situations.
Conclusions:
- PerM-MoE offers a robust and flexible solution for Alzheimer's disease progression prediction using multimodal neuroimaging, particularly excelling in clinically relevant scenarios with missing data.
- The independent router design is key to PerM-MoE's improved performance and adaptability.
- This approach advances the utility of multimodal data for forecasting cognitive decline in Alzheimer's disease.
Related Concept Videos
Alzheimer's Disease: Overview
2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
